Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) has shared an announcement.
BioDlink International Company Limited, along with its subsidiaries, operates in the biotechnology sector, focusing on the development and commercialization of biopharmaceutical products. The company is listed on the Hong Kong Stock Exchange and has a significant shareholder, Center Laboratories, Inc., listed on the Taipei Exchange. The company announced a 23% decrease in revenue for the nine months ending September 30, 2025, compared to the same period in 2024, due to increased market competition for its self-developed products. This financial update, extracted from unaudited management accounts, highlights fluctuating operational results, advising shareholders and investors to exercise caution.
The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
More about TOT BIOPHARM International Co. Ltd.
Average Trading Volume: 318,015
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$1.45B
For a thorough assessment of 1875 stock, go to TipRanks’ Stock Analysis page.